MetLife Investment Advisors LLC purchased a new stake in shares of Allogene Therapeutics Inc (NASDAQ:ALLO) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 12,636 shares of the company’s stock, valued at approximately $340,000.
A number of other large investors have also bought and sold shares of the stock. Barclays PLC acquired a new position in Allogene Therapeutics during the fourth quarter valued at $27,000. Partner Investment Management L.P. acquired a new position in Allogene Therapeutics during the fourth quarter valued at $135,000. Citigroup Inc. acquired a new position in Allogene Therapeutics during the fourth quarter valued at $152,000. Strs Ohio acquired a new position in Allogene Therapeutics during the fourth quarter valued at $156,000. Finally, American International Group Inc. acquired a new position in Allogene Therapeutics during the fourth quarter valued at $379,000. 51.60% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ ALLO opened at $25.94 on Tuesday. Allogene Therapeutics Inc has a one year low of $21.67 and a one year high of $35.55. The stock has a market capitalization of $3.20 billion and a price-to-earnings ratio of -3.94.
ALLO has been the topic of several recent analyst reports. William Blair initiated coverage on Allogene Therapeutics in a research report on Wednesday, March 13th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. reissued a “hold” rating and set a $29.00 price target on shares of Allogene Therapeutics in a research report on Monday, March 11th. Zacks Investment Research raised Allogene Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research report on Monday, January 7th. Cowen reissued a “buy” rating on shares of Allogene Therapeutics in a research report on Friday, March 8th. Finally, Raymond James initiated coverage on Allogene Therapeutics in a research report on Thursday, March 14th. They set an “outperform” rating and a $40.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $36.83.
WARNING: This news story was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4296198/12636-shares-in-allogene-therapeutics-inc-allo-acquired-by-metlife-investment-advisors-llc.html.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.
Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics Inc (NASDAQ:ALLO).
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.